ArticleProbiotics and antimicrobial proteins2026
Recombinant NK1 Protein and LEDs: An Innovative Strategy to Counteract Resistant Staphylococcus pseudintermedius and Pseudomonas aeruginosa Strains.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Graphene Oxide and Methylglyoxal: a combined strategy against chronic wound pathogens.Applied microbiology and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase in multi-drug-resistant strains represents a global challenge that strongly underlines the importance of the search for new eco-sustainable strategies. The aim of this work was to suggest a non-antibiotic approach to counteract resistant Staphylococcus pseudintermedius and Pseudomonas aeruginosa strains in planktonic and sessile phases. The proposed strategy includes the combination of natural spliced variant of hepatocyte growth factor NK1, a protein produced by recombinant DNA technology in Pichia pastoris expression system and Light-Emitting Diodes (LEDs). The antimicrobial action was determined by Minimum Inhibitory Concentration, Minimum Bactericidal Concentration, and CFU/ml evaluations. The anti-virulence action was performed by measuring P. aeruginosa motility and twitching and anti-S. pseudintermedius and -P. aeruginosa biofilms. Recombinant NK1 and LEDs alone and combined with each other showed relevant antimicrobial and anti-virulence effects. In particular, when NK1 was combined with LEDs, significant CFU/ml reduction (up to 85.98% reduction with respect to the control) after 24 h of contact, P. aeruginosa swimming/swarming/twitching halos reduction (up to 60% reduction with respect to the control) and bacterial anti-biofilm formation action was obtained. The obtained results demonstrated the innovative and interesting non-antibiotic strategy formed by recombinant NK1 protein and LEDs to affect the S. pseudintermedius and P. aeruginosa growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.